Abstract
With more than 6 years of follow‐up in the phase III PALOMA‐3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR‐positive, HER2‐negative advanced breast cancer that progressed on prior endocrine therapy.
Publication types
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms* / drug therapy
-
Female
-
Fulvestrant* / therapeutic use
-
Humans
-
Piperazines* / therapeutic use
-
Pyridines* / therapeutic use
-
Receptor, ErbB-2 / therapeutic use
Substances
-
Piperazines
-
Pyridines
-
Fulvestrant
-
Receptor, ErbB-2
-
palbociclib